Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature

Background: More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 years, and many patients also have a substantial number of age-associated impairments that need to be...

Descripción completa

Detalles Bibliográficos
Autores: Guillem, V, Climent, MA, Cassinello, J, Esteban, E, Castellano, D, Gonzalez-Larriba, JL, Maroto, P, Camps, C
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p8682
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8682
Access Level:acceso abierto
Palabra clave:Muscle-invasive bladder cancer
Urothelial carcinoma
Neoadjuvant chemotherapy
Adjuvant chemotherapy
Unfit
id ES_65ef7e48aa3e589f2e2f8932d697347e
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p8682
network_acronym_str ES
network_name_str España
repository_id_str
spelling Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literatureGuillem, VCliment, MACassinello, JEsteban, ECastellano, DGonzalez-Larriba, JLMaroto, PCamps, CMuscle-invasive bladder cancerUrothelial carcinomaNeoadjuvant chemotherapyAdjuvant chemotherapyUnfitBackground: More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 years, and many patients also have a substantial number of age-associated impairments that need to be considered when planning therapeutic interventions. Case presentation: Here, we report the case of a 63-year-old man with a cT3b urothelial carcinoma which was surgically removed. No neoadjuvant or adjuvant chemotherapy was administered. After 18 months a lung metastasis was confirmed and resected but no chemotherapy was given after surgery. Twelve months later, the patient relapsed and was treated with a combination of gemcitabine and cisplatin and after a decline in renal function the treatment was changed to a combination of carboplatin and gemcitabine which resulted in a partial response which lasted 8 months. Following this vinflunine was administered as a second line treatment. Here we review the evidence available in the literature regarding the suitability of different treatment options for managing muscle-invasive bladder cancer at each step of the case presentation. Conclusion: Bladder cancer treatment requires a multidisciplinary approach. Although, depending on the clinical characteristics of the patient, there are some controversial points in the management of this pathology we hope that the scientific data and the clinical trials reviewed in this case report, can help to guide physicians to make more rational decisions regarding the management of these patients.BMC2015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8682BMC UrologyISSN: 14712490reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p86822026-06-14T12:41:47Z
dc.title.none.fl_str_mv Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
title Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
spellingShingle Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
Guillem, V
Muscle-invasive bladder cancer
Urothelial carcinoma
Neoadjuvant chemotherapy
Adjuvant chemotherapy
Unfit
title_short Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
title_full Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
title_fullStr Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
title_full_unstemmed Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
title_sort Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature
dc.creator.none.fl_str_mv Guillem, V
Climent, MA
Cassinello, J
Esteban, E
Castellano, D
Gonzalez-Larriba, JL
Maroto, P
Camps, C
author Guillem, V
author_facet Guillem, V
Climent, MA
Cassinello, J
Esteban, E
Castellano, D
Gonzalez-Larriba, JL
Maroto, P
Camps, C
author_role author
author2 Climent, MA
Cassinello, J
Esteban, E
Castellano, D
Gonzalez-Larriba, JL
Maroto, P
Camps, C
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Muscle-invasive bladder cancer
Urothelial carcinoma
Neoadjuvant chemotherapy
Adjuvant chemotherapy
Unfit
topic Muscle-invasive bladder cancer
Urothelial carcinoma
Neoadjuvant chemotherapy
Adjuvant chemotherapy
Unfit
description Background: More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 years, and many patients also have a substantial number of age-associated impairments that need to be considered when planning therapeutic interventions. Case presentation: Here, we report the case of a 63-year-old man with a cT3b urothelial carcinoma which was surgically removed. No neoadjuvant or adjuvant chemotherapy was administered. After 18 months a lung metastasis was confirmed and resected but no chemotherapy was given after surgery. Twelve months later, the patient relapsed and was treated with a combination of gemcitabine and cisplatin and after a decline in renal function the treatment was changed to a combination of carboplatin and gemcitabine which resulted in a partial response which lasted 8 months. Following this vinflunine was administered as a second line treatment. Here we review the evidence available in the literature regarding the suitability of different treatment options for managing muscle-invasive bladder cancer at each step of the case presentation. Conclusion: Bladder cancer treatment requires a multidisciplinary approach. Although, depending on the clinical characteristics of the patient, there are some controversial points in the management of this pathology we hope that the scientific data and the clinical trials reviewed in this case report, can help to guide physicians to make more rational decisions regarding the management of these patients.
publishDate 2015
dc.date.none.fl_str_mv 2015
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8682
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8682
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv BMC Urology
ISSN: 14712490
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409779270549504
score 15.81155

Similares en LA Referencia